Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Emalex Biosciences Inc.
With
Psyadon Pharma
The purpose of this study is to determine if ecopipam is able to stop urges to gamble in patients diagnosed with Pathological Gambling. Nerves communicate with each other by releasing chemicals called "neurotransmitters". One of these neurotransmitters in the brain is called "dopamine". After dopamine is released by the nerve it "talks" to other nerves by interacting with receptors that are unique to that neurotransmitter. Ecopipam is a drug that selectively blocks one family of dopamine receptors. Some scientists believe that the urge to gamble is related to having too much dopamine in the brain. By blocking the receptors that dopamine uses, ecopipam may be able to relieve the urge to gamble.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be diagnosed with Pathological Gambling according to DSMIV criteria
Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening
Subject must have gambling urges of at least moderate intensity
You may not be if
Subjects must not have unstable medical illness or clinically significant abnormalities on lab tests, ECG, or physical exam
Subjects with major depressive episode within the last 2 years
Subjects with a history of attempted suicide
Subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide
Subjects with a history of epilepsy or seizures
Subjects with a myocardial infarction (heart attack) with in the last 6 months
Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder
Subjects with current of recent DSM-IV diagnosis of substance abuse or dependence (with the exception of nicotine)
